| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5313 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2769 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1667 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1335 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 739 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 589 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 331 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 274 | 2021 |
| Vertical T cell immunodominance and epitope entropy determine HIV-1 escape MKP Liu, N Hawkins, AJ Ritchie, VV Ganusov, V Whale, S Brackenridge, ... The Journal of clinical investigation 123 (1), 2012 | 216 | 2012 |
| Modification of in vivo and in vitro T-and B-cell-mediated immune responses by the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone AJ Ritchie, AOW Yam, KM Tanabe, SA Rice, MA Cooley Infection and immunity 71 (8), 4421-4431, 2003 | 149 | 2003 |
| The Pseudomonas aeruginosa Quorum-Sensing Molecule N-3-(Oxododecanoyl)-l-Homoserine Lactone Inhibits T-Cell Differentiation and Cytokine Production by … AJ Ritchie, A Jansson, J Stallberg, P Nilsson, P Lysaght, MA Cooley Infection and immunity 73 (3), 1648-1655, 2005 | 120 | 2005 |
| The immunomodulatory Pseudomonas aeruginosa signalling molecule N‐(3‐oxododecanoyl)‐l‐homoserine lactone enters mammalian cells in an unregulated … AJ Ritchie, C Whittall, JJ Lazenby, SR Chhabra, DI Pritchard, MA Cooley Immunology and cell biology 85 (8), 596-602, 2007 | 80 | 2007 |
| Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial M Madhavan, AJ Ritchie, J Aboagye, D Jenkin, S Provstgaad-Morys, ... EBioMedicine 85, 2022 | 75 | 2022 |
| Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination K Hillson, SC Clemens, SA Madhi, M Voysey, AJ Pollard, AM Minassian The Lancet 398 (10312), 1683-1684, 2021 | 71 | 2021 |
| Differences in HIV-specific T cell responses between HIV-exposed and-unexposed HIV-seronegative individuals AJ Ritchie, SL Campion, J Kopycinski, Z Moodie, ZM Wang, K Pandya, ... Journal of virology 85 (7), 3507-3516, 2011 | 51 | 2011 |
| Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs CCD Joe, J Jiang, T Linke, Y Li, S Fedosyuk, G Gupta, A Berg, ... Biotechnology and bioengineering 119 (1), 48-58, 2022 | 47 | 2022 |
| Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection AJ Ritchie, F Cai, NMG Smith, S Chen, H Song, S Brackenridge, ... Retrovirology 14, 20-24, 2014 | 37 | 2014 |
| Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components S Fedosyuk, T Merritt, MP Peralta-Alvarez, SJ Morris, A Lam, N Laroudie, ... Vaccine 37 (47), 6951-6961, 2019 | 35 | 2019 |
| Normal prion protein is expressed on exosomes isolated from human plasma. AJ Ritchie, DM Crawford, DJP Ferguson, J Burthem, DJ Roberts British journal of haematology 163 (5), 2013 | 32 | 2013 |
| Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners P Pala, J Serwanga, C Watera, AJ Ritchie, Z Moodie, M Wang, ... Journal of virology 87 (16), 9053-9063, 2013 | 24 | 2013 |
